Brokers Issue Forecasts for Alvotech FY2026 Earnings

Alvotech (NASDAQ:ALVO) – Equities research analysts at Northland Securities issued their FY2026 earnings per share estimates for shares of Alvotech in a research note issued on Thursday, March 19th. Northland Securities analyst C. Byrnes forecasts that the company will post earnings of ($0.08) per share for the year. The consensus estimate for Alvotech’s current full-year earnings is ($0.07) per share. Northland Securities also issued estimates for Alvotech’s FY2027 earnings at ($0.01) EPS.

ALVO has been the subject of several other reports. UBS Group decreased their price objective on shares of Alvotech from $10.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alvotech in a research report on Wednesday, January 21st. Zacks Research upgraded Alvotech from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 19th. Morgan Stanley set a $10.00 price objective on Alvotech in a report on Wednesday, December 3rd. Finally, Barclays cut their price objective on Alvotech from $5.00 to $4.00 and set an “underweight” rating on the stock in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $7.60.

Alvotech Trading Down 6.0%

Shares of NASDAQ:ALVO opened at $3.13 on Monday. The firm has a market cap of $943.63 million, a PE ratio of 31.30 and a beta of 0.16. The company has a fifty day simple moving average of $4.46 and a 200 day simple moving average of $5.77. Alvotech has a 12-month low of $3.03 and a 12-month high of $11.85.

Alvotech (NASDAQ:ALVO) last released its earnings results on Wednesday, March 18th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of $0.13 by ($0.50). Alvotech had a net margin of 4.74% and a negative return on equity of 12.84%. The business had revenue of $173.20 million for the quarter, compared to analysts’ expectations of $162.20 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ALVO. Millennium Management LLC grew its position in shares of Alvotech by 1,707.7% during the 4th quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock valued at $1,832,000 after buying an additional 337,417 shares during the last quarter. Gilder Gagnon Howe & Co. LLC bought a new position in Alvotech in the second quarter worth about $1,782,000. Norges Bank acquired a new position in Alvotech in the second quarter valued at approximately $1,656,000. Goldman Sachs Group Inc. boosted its stake in Alvotech by 88.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after acquiring an additional 122,089 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Alvotech by 2.7% during the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock valued at $35,481,000 after purchasing an additional 114,255 shares during the last quarter.

Trending Headlines about Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: UBS reiterated a Buy on ALVO and cut its price target from $10 to $6, framing regulatory setbacks as largely priced in while pointing to underlying biosimilar strength that supports upside. Article Title
• Positive Sentiment: Coverage pieces highlight Alvotech’s ongoing execution in the biosimilar market and argue for continued growth potential, which could be supportive if revenue trends and margin progress continue. Alvotech Charts Course for Continued Growth in Biosimilar Market
• Positive Sentiment: Northland Securities published commentary on Alvotech’s FY2026 results (revenue beat but EPS miss in recent quarter), providing additional analyst attention that may help reprice the stock as investors parse forward guidance and pipeline milestones. Northland Securities Comments on Alvotech FY2026 Earnings
• Neutral Sentiment: Short-interest reports are inconsistent: one clean print shows a meaningful decline to ~2.46M shares short (≈0.8% of shares) as of March 13 with a short-interest ratio ~3.7 days — a modest short base. However, multiple March 23–24 data entries report “0 shares” (likely reporting glitches), so short-interest trends should be treated cautiously.
• Negative Sentiment: Barclays cut its price target from $5 to $4 and maintained an Underweight rating, a bearish signal that likely pressured the stock alongside broader downgrades. Article Title
• Negative Sentiment: Analyst target reductions overall (UBS lowered its PT despite keeping a Buy; Barclays trimmed target and kept Underweight) increase near-term uncertainty and likely contributed to the share decline as investors weigh regulatory risk, earnings misses, and execution against long-term biosimilar opportunity. Alvotech: Regulatory Setbacks Priced In…

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).